DUBLIN, Apr. 12, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the "Global ADME (Absorption, Distribution, Metabolism And Elimination) Toxicology Testing Market, 2013 to 2022" report to their offering.
The ADME toxicology testing was valued at USD 6,986.2 Mn in 2015, and is expected to reach USD 14,319.9 Mn by 2022, expanding at a CAGR of 10.6% from 2016 to 2022.
One of the key factors responsible for late stage drug failures is the inability of drug candidates to imitate in humans the safety profile witnessed in animal models. Before introduction and acceptance of ADME toxicology testing, drug development process included toxicity and efficacy testing in in-vivo environment which was responsible for late stage failure of drugs in human body due to anatomical and genetic differences between animals and humans. To overcome this barrier of drug failure manufacturers across the globe opted for ADME toxicity testing in early drug developmental phases of pre-clinical trials.
Increasing adoption of ADME toxicity testing as cost and time curbing tool is further expected to drive growth of this market. Introduction of technologically advanced computer based testing models are additionally fueling growth of this market. According to market stakeholders, recently pre-clinical ADME toxicology testing is emerging to take on a new application in the drug-discovery venture capital (VC) industry's financial decision that corresponds in importance and scope to its established role in the scientific decisions of drug discovery firms.
Key Market Movements:
- Rising application of ADME toxicology testing by pharmaceuticals and biotechnology companies.
- Growing concerns over application of animals in clinical trials.
- Increase in demand of cell-based assays in drug discovery.
- Escalating adoption of ADME toxicity testing as cost and time curbing tool.
- Cellartis AB
- Thermo Fisher Scientific, Inc.
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Caliper Life Sciences, Inc.
- Promega Corporation
- Beckman Coulter, Inc.
- Optivia Biotechnology, Inc.
- Cyprotex PLC
- Molecular Discovery Ltd.
Key Topics Covered:
Chapter 1 Preface
Chapter 2 Executive Summary
Chapter 3 Global ADME Toxicology Testing Market: Market Dynamics and Outlook
Chapter 4 Global ADME Toxicology Testing Market, by Product Type
Chapter 5 Global ADME Toxicology Testing Market, by Technology Type
Chapter 6 Global ADME Toxicology Testing Market, by Geography
Chapter 7 Future Growth Advocacies
Chapter 8 Company Profiles
For more information about this report visit http://www.researchandmarkets.com/research/shdv6r/global_adme
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-adme-absorption-distribution-metabolism-and-elimination-toxicology-testing-market-expanding-at-a-cagr-of-106-by-2022---research-and-markets-300438587.html
SOURCE Research and Markets